In a recent publication by the Journal of the Formosan Medical Association, a pivotal discussion has been put forth emphasizing the need for international uniformity in the terminology and diagnostic guidelines for non-alcoholic fatty liver disease (NAFLD). This considerable shift in the medical approach to NAFLD, highlighted by Yu-Ming Cheng from the Department of Gastroenterology and Hepatology at Tung’s Taichung MetroHarbor Hospital, Taiwan and Chia-Chi Wang from the Department of Gastroenterology at Taipei Tzu Chi Hospital, stands to have far-reaching implications on how the condition is diagnosed, treated, and perceived globally.

The Call for Name Changes and Reshaped Criteri

The details, outlined in the DOI: 10.1016/j.jfma.2024.01.014, come at a relevant time when the prevalence of NAFLD is skyrocketing, further burdening healthcare systems already struggling with an array of chronic diseases. It cites that a consensus is forming among experts that the term “non-alcoholic fatty liver disease” may no longer be purposeful or reflect the full spectrum of the disease. A more apt nomenclature and refined criteria are in demand that accurately describe the pathophysiology and risk factors beyond the absence of significant alcohol consumption.

The Importance of Uniform Diagnostic Criteria

The journal publication by Cheng and Wang underscores the necessity of creating and adopting diagnostic criteria that are universally accepted and applied. Currently, the diagnosis of NAFLD varies widely, which complicates comparisons across studies and geographical regions. This lack of uniformity also poses challenges for the implementation of treatment strategies and the assessment of intervention outcomes on a global scale.

The Impact on Research and Clinical Practice

Changing the name and diagnostic criteria of NAFLD promises to streamline ongoing research and facilitate more consistent clinical decision-making. This could lead to improved patient outcomes through more accurate diagnoses and tailored management strategies. The integration of comprehensive diagnostic criteria would also enhance collaborative research efforts, enabling a more precise analysis of epidemiological data.


1. Non-alcoholic fatty liver disease
2. NAFLD diagnostic criteria
3. Global health uniformity
4. Liver disease nomenclature
5. Gastroenterological standards

Continuing the Dialogue and Forging Ahead

While the conversation has been initiated and is moving in a promising direction, the paper conveys that much work remains. Embracing global uniformity will involve input and commitment from a multitude of stakeholders, ranging from clinicians and researchers to policymakers and patient advocacy groups.


1. Cheng, Y.-M., & Wang, C.-C. (2024). Achieving global uniformity for the new name and diagnostic criteria of non-alcoholic fatty liver disease. Journal of the Formosan Medical Association.

2. Eslam, M., Sanyal, A. J., & George, J. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7), 1999-2014.e1.

3. Rinella, M. E. (2015). Nonalcoholic fatty liver disease: A systematic review. JAMA, 313 (22), 2263-2273.

4. Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.

5. Vos, M. B., & Lavine, J. E. (2013). Dietary fructose in nonalcoholic fatty liver disease. Hepatology, 57(6), 2525-2531.

Declaration of Competing Interest

In line with transparent scientific communication, it is disclosed that all authors in the publication from the Journal of the Formosan Medical Association declare no conflict of interest in conjunction with the presented research and discussion.

In conclusion, the forward-looking perspective offered by the publication illuminates the road ahead towards achieving global uniformity in the diagnosis and nomenclature of non-alcoholic fatty liver disease. Such synchronization across the medical field would foster better understanding, management, and ultimately, patient care for this increasing health concern.

The complete article can be accessed with the provided DOI, and it becomes an essential read for professionals vested in the fields of gastroenterology, hepatology, and primary health care. Through ongoing dialogue and collaborative efforts, it is envisioned that consensus and coherence can eventually be attained, leading to profound benefits for the millions affected by this disease worldwide.